Pair Name	Evodiamine, Gemcitabine
Partner Name	Gemcitabine
Disease Info	[ICD-11: 2B62.Z]	Tongue cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BCL-xL	hsa598
	Down-regulation	Expression	RELA	hsa5970
In Vitro Model	CAL-27	Tongue adenosquamous carcinoma	Homo sapiens (Human)	CVCL_1107
	Tca8113	Human papillomavirus-related cervical adenocarcinoma	Homo sapiens (Human)	CVCL_6851
In Vivo Model	CAL-27 cells (2×10⁶) were injected subcutaneously into the right armpit regions of nude mice.
Result	The results of this study showed that EVO may inhibit cancer cells by suppressing NF-κB activity, and in combination with GEM, it may increase the chemosensitivity of tongue squamous cancer cells, thereby improving the treatment response.

Pair Name	Evodiamine, Doxorubicin
Partner Name	Doxorubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BIRC2	hsa329
	Down-regulation	Expression	BIRC5	hsa332
	Up-regulation	Activity	CASP7	hsa840
	Up-regulation	Activity	CASP9	hsa842
	Down-regulation	Expression	KRAS	hsa3845
	Down-regulation	Phosphorylation	MAP2K7	hsa5609
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Up-regulation	Activity	PARP1	hsa142
	Down-regulation	Expression	XIAP	hsa331
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
Result	Our results indicated that EVO enhanced the apoptotic action of DOX by inhibiting the Ras/MEK/ERK cascade and the expression of IAPs without inhibiting the expression and activity of P-glycoprotein (P-gp). Taken together, our data indicate that EVO, a natural product, may be useful applied alone or in combination with DOX for the treatment of resistant breast cancer.